14 February 2013Asia

India’s Patent Office revokes Sutent cancer drug patent

India’s Patent Office has revoked pharmaceutical company Sugen and licensee Pfizer’s patent for the cancer drug Sutent, agreeing with Indian drugs maker Cipla that it lacks inventive step.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
7 June 2013   India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.

More on this story

Asia-Pacific
7 June 2013   India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.

More on this story

Asia-Pacific
7 June 2013   India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.